Synthesis, Biological Evaluation and Quantitative Structure Activity Relationship Analysis of Nuclear-substituted Pargylines as Competitive Inhibitors of MAO-A and MAO-B
A TiO2 immobilized Ru(ii) polyazine complex: a visible-light active photoredox catalyst for oxidative cyanation of tertiary amines
作者:Pawan Kumar、Sanny Varma、Suman L. Jain
DOI:10.1039/c3ta14783e
日期:——
nanocrystalline TiO2 grafted ruthenium(II) polyazine complex was found to be an efficient visible light photoredox catalyst for the oxidativecyanation of tertiaryamines to the corresponding α-aminonitriles in high to excellent yields, using molecular oxygen as an oxidant and sodiumcyanide in acetic acid as a cyanide source. The developed photoredox catalyst could be easily recovered by simple filtration
作者:Kirsty Milne、Jianhui Sun、Esther A. Zaal、Jenna Mowat、Patrick H.N. Celie、Alexander Fish、Celia R. Berkers、Giuseppe Forlani、Fabricio Loayza-Puch、Craig Jamieson、Reuven Agami
DOI:10.1016/j.bmcl.2019.07.047
日期:2019.9
Pyrroline-5-carboxylate reductase 1 (PYCR1) is the final enzyme involved in the biosynthesis of proline and has been found to be upregulated in various forms of cancer. Due to the role of proline in maintaining the redox balance of cells and preventing apoptosis, PYCR1 is emerging as an attractive oncology target. Previous PYCR1 knockout studies led to a reduction in tumor growth. Accordingly, a small molecule inhibitor of PYCR1 could lead to new treatments for cancer, and a focused screening effort identified pargyline as a fragment-like hit. We report the design and synthesis of the first tool compounds as PYCR1 inhibitors, derived from pargyline, which were assayed to assess their ability to attenuate the production of proline. Structural activity studies have revealed the key determinants of activity, with the most potent compound (4) showing improved activity in vitro in enzyme (IC50 = 8.8 mu M) and pathway relevant effects in cell-based assays.
MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY
申请人:McElroy John F.
公开号:US20080182824A1
公开(公告)日:2008-07-31
The invention provides novel N-benzyl-N-propargyl-amines that are monoamine oxidase inhibitors, but generally exhibit little or no CNS effects.